Harpoon Therapeutics Inc. (HARP) NASDAQ
$23.01 0.02 (0.09%)
Market Cap: -
As of 03/08/24 04:00 PM EST. Market closed.
Harpoon Therapeutics Inc. (HARP)
NASDAQ
$23.01
0.02 (0.09%)
Market Cap: -
As of 03/08/24 04:00 PM EST. Market closed.
harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built ... read more
harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built upon the successful development of the bispecific (“bite™ or bispecific t cell engager”) antibody blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. harpoon’s tri-specific t-cell redirection platform -- tritac™ -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, car-t and other t-cell engaging approaches by improving ? activity against read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Merck & Co., Inc. | 10% Owner | Mar 11, 2024 | Buy | $23.00 | 21,397,205 | 492,135,715 | 1,000 | Mar 11, 2024, 03:27 PM |
HUNT RONALD | Director | Mar 23, 2023 | Buy | $1000.00 | 10,000 | 10,000,000 | 10,000 | Mar 27, 2023, 05:37 PM |
Erbez Georgia | Chief Financial Officer | Sep 22, 2021 | Buy | $8.10 | 10,300 | 83,430 | 19,215 | Sep 22, 2021, 09:30 PM |
New Leaf Ventures III, L.P. | 10% Owner | Jan 11, 2021 | Buy | $17.00 | 235,294 | 3,999,998 | 913,860 | Aug 12, 2021, 04:15 PM |
HUNT RONALD | Director | Jan 11, 2021 | Buy | $17.00 | 235,294 | 3,999,998 | 913,860 | Aug 12, 2021, 04:15 PM |
Wesche Holger | Chief Scientific Officer | Jul 01, 2021 | Option Exercise | $0.60 | 10,000 | 6,000 | 62,852 | Jul 06, 2021, 06:01 PM |
Wesche Holger | Chief Scientific Officer | Jul 01, 2021 | Sale | $14.00 | 10,000 | 140,000 | 52,852 | Jul 06, 2021, 06:01 PM |
GADICKE ANSBERT | 10% Owner | Jun 02, 2021 | Sale | $20.50 | 25,118 | 514,919 | 6,328,095 | Jun 02, 2021, 06:09 PM |
GADICKE ANSBERT | 10% Owner | Jun 01, 2021 | Sale | $20.44 | 18,491 | 377,956 | 6,353,213 | Jun 02, 2021, 06:09 PM |
GADICKE ANSBERT | 10% Owner | May 28, 2021 | Sale | $21.12 | 13,885 | 293,315 | 6,374,904 | Jun 02, 2021, 06:09 PM |
GADICKE ANSBERT | 10% Owner | May 27, 2021 | Sale | $20.26 | 13,961 | 282,850 | 6,385,589 | May 27, 2021, 07:40 PM |
GADICKE ANSBERT | 10% Owner | May 26, 2021 | Sale | $20.04 | 3,198 | 64,088 | 6,399,550 | May 27, 2021, 07:40 PM |
GADICKE ANSBERT | 10% Owner | May 24, 2021 | Sale | $20.12 | 5,000 | 100,600 | 6,402,748 | May 24, 2021, 08:11 PM |
GADICKE ANSBERT | 10% Owner | May 21, 2021 | Sale | $20.21 | 10,907 | 220,430 | 6,407,748 | May 24, 2021, 08:11 PM |
GADICKE ANSBERT | 10% Owner | May 20, 2021 | Sale | $20.34 | 11,713 | 238,242 | 6,418,655 | May 20, 2021, 07:20 PM |
GADICKE ANSBERT | 10% Owner | May 19, 2021 | Sale | $20.39 | 17,833 | 363,615 | 6,430,368 | May 20, 2021, 07:20 PM |
GADICKE ANSBERT | 10% Owner | May 18, 2021 | Sale | $20.67 | 18,402 | 380,369 | 6,448,201 | May 20, 2021, 07:20 PM |
GADICKE ANSBERT | 10% Owner | May 17, 2021 | Sale | $20.07 | 4,666 | 93,647 | 6,466,603 | May 17, 2021, 05:23 PM |
GADICKE ANSBERT | 10% Owner | May 14, 2021 | Sale | $20.04 | 6,900 | 138,276 | 6,471,269 | May 17, 2021, 05:23 PM |
GADICKE ANSBERT | 10% Owner | May 13, 2021 | Sale | $20.06 | 4,855 | 97,391 | 6,478,169 | May 17, 2021, 05:23 PM |
GADICKE ANSBERT | 10% Owner | May 05, 2021 | Sale | $22.52 | 10,172 | 229,107 | 6,551,345 | May 06, 2021, 04:05 PM |
GADICKE ANSBERT | 10% Owner | Apr 21, 2021 | Sale | $18.97 | 8,972 | 170,229 | 7,020,675 | Apr 22, 2021, 04:04 PM |
GADICKE ANSBERT | 10% Owner | Apr 16, 2021 | Sale | $19.86 | 5,847 | 116,110 | 7,061,697 | Apr 20, 2021, 06:07 PM |
GADICKE ANSBERT | 10% Owner | Apr 20, 2021 | Sale | $18.71 | 22,249 | 416,382 | 7,029,926 | Apr 20, 2021, 06:07 PM |
GADICKE ANSBERT | 10% Owner | Apr 19, 2021 | Sale | $19.30 | 10,056 | 194,059 | 7,051,441 | Apr 20, 2021, 06:07 PM |
MPM BioVentures 2014, L.P. | Former 10% Owner | Apr 13, 2021 | Sale | $19.46 | 1,943 | 37,806 | 3,223,853 | Apr 15, 2021, 08:01 PM |
MPM BioVentures 2014, L.P. | Former 10% Owner | Apr 15, 2021 | Sale | $20.49 | 1,052 | 21,555 | 3,220,844 | Apr 15, 2021, 08:01 PM |
MPM BioVentures 2014, L.P. | Former 10% Owner | Apr 14, 2021 | Sale | $20.77 | 1,671 | 34,714 | 3,223,446 | Apr 15, 2021, 08:01 PM |
GADICKE ANSBERT | 10% Owner | Apr 15, 2021 | Sale | $20.49 | 8,696 | 178,181 | 7,067,244 | Apr 15, 2021, 08:00 PM |
GADICKE ANSBERT | 10% Owner | Apr 14, 2021 | Sale | $20.77 | 13,806 | 286,809 | 7,088,746 | Apr 15, 2021, 08:00 PM |
GADICKE ANSBERT | 10% Owner | Apr 13, 2021 | Sale | $19.46 | 16,054 | 312,369 | 7,092,108 | Apr 15, 2021, 08:00 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Apr 12, 2021 | Sale | $21.02 | 2,496 | 52,460 | 3,226,369 | Apr 13, 2021, 04:12 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Apr 09, 2021 | Sale | $23.67 | 10,300 | 243,801 | 3,228,006 | Apr 13, 2021, 04:12 PM |
Wesche Holger | Chief Scientific Officer | Apr 01, 2021 | Option Exercise | $0.60 | 10,000 | 6,000 | 62,852 | Apr 05, 2021, 05:00 PM |
Wesche Holger | Chief Scientific Officer | Apr 01, 2021 | Sale | $20.45 | 10,000 | 204,491 | 53,352 | Apr 05, 2021, 05:00 PM |
Erbez Georgia | Chief Financial Officer | Feb 17, 2021 | Option Exercise | $2.12 | 25,000 | 53,000 | 72,292 | Feb 18, 2021, 08:31 AM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 10, 2021 | Sale | $20.00 | 183,051 | 3,661,020 | 3,238,306 | Feb 12, 2021, 05:03 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 10, 2021 | Sale | $20.00 | 183,051 | 3,661,020 | 3,238,306 | Feb 12, 2021, 05:03 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 09, 2021 | Sale | $20.25 | 9,400 | 190,350 | 3,421,357 | Feb 09, 2021, 06:14 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 08, 2021 | Sale | $20.04 | 72,128 | 1,445,445 | 3,430,757 | Feb 09, 2021, 06:14 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 05, 2021 | Sale | $20.01 | 10,172 | 203,542 | 3,502,885 | Feb 09, 2021, 06:14 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 02, 2021 | Sale | $20.13 | 48,421 | 974,715 | 3,584,709 | Feb 04, 2021, 07:30 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 04, 2021 | Sale | $20.37 | 29,730 | 605,600 | 3,513,057 | Feb 04, 2021, 07:30 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 03, 2021 | Sale | $20.21 | 41,922 | 847,244 | 3,542,787 | Feb 04, 2021, 07:30 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Jan 27, 2021 | Sale | $20.00 | 706,825 | 14,136,500 | 3,633,130 | Jan 27, 2021, 08:35 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Jan 26, 2021 | Sale | $21.08 | 1,363 | 28,732 | 4,339,955 | Jan 27, 2021, 08:35 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Jan 25, 2021 | Sale | $21.23 | 13,006 | 276,117 | 4,341,318 | Jan 27, 2021, 08:35 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Jan 22, 2021 | Sale | $21.72 | 24,695 | 536,375 | 4,354,324 | Jan 22, 2021, 08:16 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Jan 21, 2021 | Sale | $22.22 | 26,066 | 579,095 | 4,384,106 | Jan 22, 2021, 08:16 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Jan 20, 2021 | Sale | $24.04 | 17,694 | 425,291 | 4,508,731 | Jan 22, 2021, 08:16 PM |
Wesche Holger | Chief Scientific Officer | Jan 04, 2021 | Option Exercise | $0.60 | 10,000 | 6,000 | 62,852 | Jan 06, 2021, 06:25 PM |
Wesche Holger | Chief Scientific Officer | Jan 04, 2021 | Sale | $18.38 | 10,000 | 183,837 | 59,752 | Jan 06, 2021, 06:25 PM |
Wesche Holger | Chief Scientific Officer | Oct 01, 2020 | Option Exercise | $0.60 | 10,000 | 6,000 | 62,669 | Oct 05, 2020, 04:25 PM |
Wesche Holger | Chief Scientific Officer | Oct 01, 2020 | Sale | $16.27 | 10,000 | 162,737 | 53,669 | Oct 05, 2020, 04:25 PM |
Erbez Georgia | Chief Financial Officer | Aug 19, 2020 | Buy | $11.40 | 5,000 | 57,000 | 8,915 | Aug 20, 2020, 06:36 PM |
Erbez Georgia | Chief Financial Officer | Aug 18, 2020 | Buy | $11.60 | 2,098 | 24,337 | 3,915 | Aug 20, 2020, 06:36 PM |
Erbez Georgia | Chief Financial Officer | Jul 31, 2020 | Buy | $10.92 | 1,817 | 19,842 | 1,817 | Aug 04, 2020, 08:32 AM |
Wesche Holger | Chief Scientific Officer | Jul 01, 2020 | Option Exercise | $0.60 | 10,000 | 6,000 | 62,669 | Jul 02, 2020, 07:18 PM |
Wesche Holger | Chief Scientific Officer | Jul 01, 2020 | Sale | $16.20 | 10,000 | 161,989 | 52,669 | Jul 02, 2020, 07:18 PM |
Arix Bioscience plc | 10% Owner | May 28, 2020 | Sale | $21.33 | 366,591 | 7,820,926 | 2,193,704 | May 29, 2020, 04:32 PM |
Arix Bioscience plc | 10% Owner | May 27, 2020 | Sale | $22.39 | 12,064 | 270,144 | 2,560,295 | May 29, 2020, 04:32 PM |
Sacks Natalie | Chief Medical Officer | May 18, 2020 | Option Exercise | $2.12 | 1,522 | 3,227 | 47,276 | May 20, 2020, 06:34 PM |
Sacks Natalie | Chief Medical Officer | May 18, 2020 | Sale | $14.77 | 1,522 | 22,479 | 45,754 | May 20, 2020, 06:34 PM |
Wesche Holger | Chief Scientific Officer | May 12, 2020 | Option Exercise | $0.60 | 1,400 | 840 | 54,069 | May 13, 2020, 08:45 PM |
Wesche Holger | Chief Scientific Officer | May 12, 2020 | Sale | $14.09 | 1,400 | 19,720 | 52,669 | May 13, 2020, 08:45 PM |
Wesche Holger | Chief Scientific Officer | May 07, 2020 | Option Exercise | $0.60 | 5,350 | 3,210 | 58,019 | May 11, 2020, 09:37 PM |
Wesche Holger | Chief Scientific Officer | May 11, 2020 | Option Exercise | $0.60 | 1,000 | 600 | 53,669 | May 11, 2020, 09:37 PM |
Wesche Holger | Chief Scientific Officer | May 08, 2020 | Option Exercise | $0.60 | 1,000 | 600 | 53,669 | May 11, 2020, 09:37 PM |
Wesche Holger | Chief Scientific Officer | May 07, 2020 | Sale | $14.13 | 5,350 | 75,576 | 52,669 | May 11, 2020, 09:37 PM |
Wesche Holger | Chief Scientific Officer | May 11, 2020 | Sale | $14.07 | 1,000 | 14,065 | 52,669 | May 11, 2020, 09:37 PM |
Wesche Holger | Chief Scientific Officer | May 08, 2020 | Sale | $14.00 | 1,000 | 14,000 | 52,669 | May 11, 2020, 09:37 PM |
Sacks Natalie | Chief Medical Officer | May 01, 2020 | Option Exercise | $2.12 | 5,826 | 12,351 | 51,580 | May 05, 2020, 04:35 PM |
Sacks Natalie | Chief Medical Officer | May 01, 2020 | Sale | $12.07 | 5,826 | 70,301 | 45,754 | May 05, 2020, 04:35 PM |
Wesche Holger | Chief Scientific Officer | Apr 28, 2020 | Option Exercise | $0.60 | 1,250 | 750 | 53,919 | Apr 30, 2020, 04:58 PM |
Wesche Holger | Chief Scientific Officer | Apr 28, 2020 | Sale | $14.05 | 1,250 | 17,565 | 52,669 | Apr 30, 2020, 04:58 PM |
Sacks Natalie | Chief Medical Officer | Apr 17, 2020 | Option Exercise | $2.12 | 1,021 | 2,165 | 46,775 | Apr 17, 2020, 07:10 PM |
Sacks Natalie | Chief Medical Officer | Apr 16, 2020 | Option Exercise | $2.12 | 500 | 1,060 | 46,254 | Apr 17, 2020, 07:10 PM |
Sacks Natalie | Chief Medical Officer | Apr 17, 2020 | Sale | $12.08 | 1,021 | 12,330 | 45,754 | Apr 17, 2020, 07:10 PM |
Sacks Natalie | Chief Medical Officer | Apr 16, 2020 | Sale | $12.00 | 500 | 6,000 | 45,754 | Apr 17, 2020, 07:10 PM |
Sacks Natalie | Chief Medical Officer | Apr 13, 2020 | Option Exercise | $2.12 | 4,556 | 9,659 | 50,310 | Apr 15, 2020, 04:48 PM |
Sacks Natalie | Chief Medical Officer | Apr 13, 2020 | Sale | $12.06 | 4,556 | 54,959 | 45,754 | Apr 15, 2020, 04:48 PM |
Sacks Natalie | Chief Medical Officer | Apr 07, 2020 | Option Exercise | $2.12 | 570 | 1,208 | 46,324 | Apr 08, 2020, 06:10 PM |
Sacks Natalie | Chief Medical Officer | Apr 06, 2020 | Option Exercise | $2.12 | 700 | 1,484 | 46,454 | Apr 08, 2020, 06:10 PM |
Sacks Natalie | Chief Medical Officer | Apr 06, 2020 | Sale | $12.00 | 700 | 8,401 | 45,754 | Apr 08, 2020, 06:10 PM |
Sacks Natalie | Chief Medical Officer | Apr 07, 2020 | Sale | $12.00 | 570 | 6,840 | 45,754 | Apr 08, 2020, 06:10 PM |
Sacks Natalie | Chief Medical Officer | Mar 17, 2020 | Option Exercise | $2.12 | 1,520 | 3,222 | 47,274 | Mar 18, 2020, 05:28 PM |
Sacks Natalie | Chief Medical Officer | Mar 16, 2020 | Option Exercise | $2.12 | 1 | 2 | 45,755 | Mar 18, 2020, 05:28 PM |
Sacks Natalie | Chief Medical Officer | Mar 17, 2020 | Sale | $12.00 | 1,520 | 18,240 | 45,754 | Mar 18, 2020, 05:28 PM |
Sacks Natalie | Chief Medical Officer | Mar 16, 2020 | Sale | $12.00 | 1 | 12 | 45,754 | Mar 18, 2020, 05:28 PM |
Sacks Natalie | Chief Medical Officer | Mar 02, 2020 | Option Exercise | $2.12 | 5,826 | 12,351 | 51,580 | Mar 03, 2020, 09:31 PM |
Sacks Natalie | Chief Medical Officer | Mar 02, 2020 | Sale | $14.68 | 5,826 | 85,526 | 45,754 | Mar 03, 2020, 09:31 PM |
Sacks Natalie | Chief Medical Officer | Feb 18, 2020 | Option Exercise | $2.12 | 1,521 | 3,225 | 47,275 | Feb 20, 2020, 05:11 PM |
Sacks Natalie | Chief Medical Officer | Feb 18, 2020 | Sale | $15.00 | 1,521 | 22,815 | 45,754 | Feb 20, 2020, 05:11 PM |
Sacks Natalie | Chief Medical Officer | Feb 03, 2020 | Option Exercise | $2.12 | 5,826 | 12,351 | 51,580 | Feb 04, 2020, 08:11 PM |
Sacks Natalie | Chief Medical Officer | Feb 03, 2020 | Sale | $13.90 | 5,826 | 81,006 | 45,754 | Feb 04, 2020, 08:11 PM |
Erbez Georgia | Chief Financial Officer | Jan 21, 2020 | Buy | $14.09 | 6,700 | 94,418 | 6,700 | Jan 23, 2020, 08:34 AM |
Sacks Natalie | Chief Medical Officer | Jan 16, 2020 | Option Exercise | $2.12 | 1,521 | 3,225 | 47,275 | Jan 21, 2020, 08:05 PM |
Sacks Natalie | Chief Medical Officer | Jan 16, 2020 | Sale | $14.94 | 1,521 | 22,725 | 45,754 | Jan 21, 2020, 08:05 PM |
Wesche Holger | Chief Scientific Officer | Jan 02, 2020 | Option Exercise | $0.60 | 10,000 | 6,000 | 62,669 | Jan 06, 2020, 09:55 PM |
Wesche Holger | Chief Scientific Officer | Jan 02, 2020 | Sale | $14.40 | 10,000 | 143,987 | 52,669 | Jan 06, 2020, 09:55 PM |
Sacks Natalie | Chief Medical Officer | Jan 02, 2020 | Option Exercise | $2.12 | 5,826 | 12,351 | 51,580 | Jan 06, 2020, 09:46 PM |
Sacks Natalie | Chief Medical Officer | Jan 02, 2020 | Sale | $14.18 | 5,826 | 82,600 | 45,754 | Jan 06, 2020, 09:46 PM |
Baeuerle Patrick | Director | Dec 27, 2019 | Sale | $15.98 | 87,379 | 1,396,281 | 273,953 | Dec 30, 2019, 05:32 PM |
Sacks Natalie | Chief Medical Officer | Dec 16, 2019 | Option Exercise | $2.12 | 1,521 | 3,225 | 47,275 | Dec 18, 2019, 04:14 PM |
Sacks Natalie | Chief Medical Officer | Dec 16, 2019 | Sale | $17.02 | 1,521 | 25,888 | 45,754 | Dec 18, 2019, 04:14 PM |
Chin Mark | Director | Dec 17, 2019 | Sale | $16.83 | 12,476 | 209,969 | 2,572,359 | Dec 17, 2019, 09:23 PM |
Chin Mark | Director | Dec 16, 2019 | Sale | $17.02 | 13,080 | 222,680 | 2,584,835 | Dec 17, 2019, 09:23 PM |
Chin Mark | Director | Dec 13, 2019 | Sale | $17.21 | 11,002 | 189,341 | 2,597,915 | Dec 17, 2019, 09:23 PM |
Arix Bioscience plc | 10% Owner | Dec 17, 2019 | Sale | $16.83 | 12,476 | 209,969 | 2,572,359 | Dec 17, 2019, 07:20 PM |
Arix Bioscience plc | 10% Owner | Dec 16, 2019 | Sale | $17.02 | 13,080 | 222,680 | 2,584,835 | Dec 17, 2019, 07:20 PM |
Arix Bioscience plc | 10% Owner | Dec 13, 2019 | Sale | $17.21 | 11,002 | 189,341 | 2,597,915 | Dec 17, 2019, 07:20 PM |
Chin Mark | Director | Dec 10, 2019 | Sale | $16.91 | 131,696 | 2,227,019 | 2,608,917 | Dec 10, 2019, 08:07 PM |
Chin Mark | Director | Dec 09, 2019 | Sale | $18.16 | 103,754 | 1,884,445 | 2,817,929 | Dec 10, 2019, 08:07 PM |
Chin Mark | Director | Dec 06, 2019 | Sale | $19.15 | 47,752 | 914,222 | 2,844,367 | Dec 10, 2019, 08:07 PM |
Arix Bioscience plc | 10% Owner | Dec 10, 2019 | Sale | $16.91 | 131,696 | 2,227,019 | 2,608,917 | Dec 10, 2019, 07:27 PM |
Arix Bioscience plc | 10% Owner | Dec 09, 2019 | Sale | $18.16 | 103,754 | 1,884,445 | 2,817,929 | Dec 10, 2019, 07:27 PM |
Arix Bioscience plc | 10% Owner | Dec 06, 2019 | Sale | $19.15 | 47,752 | 914,222 | 2,844,367 | Dec 10, 2019, 07:27 PM |
Erbez Georgia | Chief Financial Officer | Dec 04, 2019 | Option Exercise | $2.12 | 47,292 | 100,259 | 47,292 | Dec 06, 2019, 04:41 PM |
Sacks Natalie | Chief Medical Officer | Dec 02, 2019 | Option Exercise | $2.12 | 5,826 | 12,351 | 51,580 | Dec 04, 2019, 04:42 PM |
Sacks Natalie | Chief Medical Officer | Dec 02, 2019 | Sale | $17.98 | 5,826 | 104,751 | 45,754 | Dec 04, 2019, 04:42 PM |
Sacks Natalie | Chief Medical Officer | Nov 18, 2019 | Option Exercise | $2.12 | 18,252 | 38,694 | 64,006 | Nov 19, 2019, 04:24 PM |
Sacks Natalie | Chief Medical Officer | Nov 18, 2019 | Sale | $13.37 | 18,252 | 243,964 | 46,754 | Nov 19, 2019, 04:24 PM |
Sacks Natalie | Chief Medical Officer | Nov 01, 2019 | Option Exercise | $2.12 | 5,826 | 12,351 | 51,580 | Nov 05, 2019, 04:09 PM |
Sacks Natalie | Chief Medical Officer | Nov 01, 2019 | Sale | $13.17 | 5,826 | 76,702 | 45,754 | Nov 05, 2019, 04:09 PM |
Sacks Natalie | Chief Medical Officer | Oct 14, 2019 | Option Exercise | $2.12 | 12,452 | 26,398 | 58,206 | Oct 16, 2019, 05:14 PM |
Sacks Natalie | Chief Medical Officer | Oct 15, 2019 | Option Exercise | $2.12 | 11,698 | 24,800 | 57,452 | Oct 16, 2019, 05:14 PM |
Sacks Natalie | Chief Medical Officer | Oct 15, 2019 | Sale | $13.21 | 11,698 | 154,481 | 45,754 | Oct 16, 2019, 05:14 PM |
Sacks Natalie | Chief Medical Officer | Oct 14, 2019 | Sale | $13.27 | 12,452 | 165,280 | 45,754 | Oct 16, 2019, 05:14 PM |
McMahon Gerald PhD | President and CEO | Jun 05, 2019 | Option Exercise | $0.60 | 169,462 | 101,677 | 172,462 | Sep 06, 2019, 07:17 PM |
McMahon Gerald PhD | President and CEO | May 14, 2019 | Buy | $10.16 | 1,000 | 10,157 | 3,000 | May 16, 2019, 08:32 AM |
McMahon Gerald PhD | President and CEO | May 08, 2019 | Buy | $10.56 | 1,000 | 10,559 | 2,000 | May 10, 2019, 08:31 AM |
McMahon Gerald PhD | President and CEO | May 03, 2019 | Buy | $10.53 | 1,000 | 10,530 | 1,000 | May 07, 2019, 04:12 PM |
Arix Bioscience plc | 10% Owner | Feb 12, 2019 | Buy | $14.00 | 428,571 | 5,999,994 | 2,892,119 | Feb 14, 2019, 06:01 PM |
UBS Oncology Impact Fund L.P. | 10% Owner | Feb 12, 2019 | Buy | $14.00 | 250,000 | 3,500,000 | 3,898,422 | Feb 14, 2019, 05:34 PM |
UBS Oncology Impact Fund L.P. | 10% Owner | Feb 12, 2019 | Sale | $14.00 | 447 | 6,258 | 3,648,422 | Feb 14, 2019, 05:34 PM |
UBS Oncology Impact Fund L.P. | 10% Owner | Feb 12, 2019 | Option Exercise | $0.05 | 127,096 | 6,253 | 3,648,869 | Feb 14, 2019, 05:34 PM |
New Leaf Ventures III, L.P. | 10% Owner | Feb 12, 2019 | Buy | $14.00 | 428,571 | 5,999,994 | 2,242,839 | Feb 14, 2019, 05:33 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 12, 2019 | Buy | $14.00 | 250,000 | 3,500,000 | 4,524,425 | Feb 14, 2019, 05:32 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 12, 2019 | Sale | $14.00 | 1,524 | 21,336 | 4,274,425 | Feb 14, 2019, 05:32 PM |
MPM BioVentures 2014, L.P. | 10% Owner | Feb 12, 2019 | Option Exercise | $0.05 | 432,119 | 21,260 | 4,275,949 | Feb 14, 2019, 05:32 PM |
HUNT RONALD | Director | Feb 12, 2019 | Buy | $14.00 | 428,571 | 5,999,994 | 2,242,839 | Feb 14, 2019, 05:30 PM |
GADICKE ANSBERT | 10% Owner | Feb 12, 2019 | Buy | $14.00 | 500,000 | 7,000,000 | 8,422,847 | Feb 14, 2019, 05:28 PM |
GADICKE ANSBERT | 10% Owner | Feb 12, 2019 | Sale | $14.00 | 1,971 | 27,594 | 7,922,847 | Feb 14, 2019, 05:28 PM |
GADICKE ANSBERT | 10% Owner | Feb 12, 2019 | Option Exercise | $0.05 | 559,215 | 27,513 | 7,924,818 | Feb 14, 2019, 05:28 PM |
Chin Mark | Director | Feb 12, 2019 | Buy | $14.00 | 428,571 | 5,999,994 | 2,892,119 | Feb 14, 2019, 05:24 PM |
EVNIN LUKE | Director | Feb 12, 2019 | Option Exercise | $14.00 | 1,524 | 21,336 | 4,274,425 | Feb 14, 2019, 05:19 PM |
EVNIN LUKE | Director | Feb 12, 2019 | Buy | $14.00 | 250,000 | 3,500,000 | 4,524,425 | Feb 14, 2019, 05:19 PM |
EVNIN LUKE | Director | Feb 12, 2019 | Option Exercise | $0.05 | 432,119 | 21,260 | 4,275,949 | Feb 14, 2019, 05:19 PM |
Owner | Relationship | Date | Value($) |
Merck & Co., Inc. | 10% Owner | 03/11/2024 | 492,135,715 |
HUNT RONALD | Director | 03/23/2023 | 10,000,000 |
Erbez Georgia | Chief Financial Officer | 09/22/2021 | 83,430 |
New Leaf Ventures III, L.P. | 10% Owner | 01/11/2021 | 3,999,998 |
HUNT RONALD | Director | 01/11/2021 | 3,999,998 |
Wesche Holger | Chief Scientific Officer | 07/01/2021 | 6,000 |
Wesche Holger | Chief Scientific Officer | 07/01/2021 | 140,000 |
GADICKE ANSBERT | 10% Owner | 06/02/2021 | 514,919 |
GADICKE ANSBERT | 10% Owner | 06/01/2021 | 377,956 |
GADICKE ANSBERT | 10% Owner | 05/28/2021 | 293,315 |
GADICKE ANSBERT | 10% Owner | 05/27/2021 | 282,850 |
GADICKE ANSBERT | 10% Owner | 05/26/2021 | 64,088 |
GADICKE ANSBERT | 10% Owner | 05/24/2021 | 100,600 |
GADICKE ANSBERT | 10% Owner | 05/21/2021 | 220,430 |
GADICKE ANSBERT | 10% Owner | 05/20/2021 | 238,242 |
GADICKE ANSBERT | 10% Owner | 05/19/2021 | 363,615 |
GADICKE ANSBERT | 10% Owner | 05/18/2021 | 380,369 |
GADICKE ANSBERT | 10% Owner | 05/17/2021 | 93,647 |
GADICKE ANSBERT | 10% Owner | 05/14/2021 | 138,276 |
GADICKE ANSBERT | 10% Owner | 05/13/2021 | 97,391 |
GADICKE ANSBERT | 10% Owner | 05/05/2021 | 229,107 |
GADICKE ANSBERT | 10% Owner | 04/21/2021 | 170,229 |
GADICKE ANSBERT | 10% Owner | 04/16/2021 | 116,110 |
GADICKE ANSBERT | 10% Owner | 04/20/2021 | 416,382 |
GADICKE ANSBERT | 10% Owner | 04/19/2021 | 194,059 |
MPM BioVentures 2014, L.P. | Former 10% Owner | 04/13/2021 | 37,806 |
MPM BioVentures 2014, L.P. | Former 10% Owner | 04/15/2021 | 21,555 |
MPM BioVentures 2014, L.P. | Former 10% Owner | 04/14/2021 | 34,714 |
GADICKE ANSBERT | 10% Owner | 04/15/2021 | 178,181 |
GADICKE ANSBERT | 10% Owner | 04/14/2021 | 286,809 |
GADICKE ANSBERT | 10% Owner | 04/13/2021 | 312,369 |
MPM BioVentures 2014, L.P. | 10% Owner | 04/12/2021 | 52,460 |
MPM BioVentures 2014, L.P. | 10% Owner | 04/09/2021 | 243,801 |
Wesche Holger | Chief Scientific Officer | 04/01/2021 | 6,000 |
Wesche Holger | Chief Scientific Officer | 04/01/2021 | 204,491 |
Erbez Georgia | Chief Financial Officer | 02/17/2021 | 53,000 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/10/2021 | 3,661,020 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/10/2021 | 3,661,020 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/09/2021 | 190,350 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/08/2021 | 1,445,445 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/05/2021 | 203,542 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/02/2021 | 974,715 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/04/2021 | 605,600 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/03/2021 | 847,244 |
MPM BioVentures 2014, L.P. | 10% Owner | 01/27/2021 | 14,136,500 |
MPM BioVentures 2014, L.P. | 10% Owner | 01/26/2021 | 28,732 |
MPM BioVentures 2014, L.P. | 10% Owner | 01/25/2021 | 276,117 |
MPM BioVentures 2014, L.P. | 10% Owner | 01/22/2021 | 536,375 |
MPM BioVentures 2014, L.P. | 10% Owner | 01/21/2021 | 579,095 |
MPM BioVentures 2014, L.P. | 10% Owner | 01/20/2021 | 425,291 |
Wesche Holger | Chief Scientific Officer | 01/04/2021 | 6,000 |
Wesche Holger | Chief Scientific Officer | 01/04/2021 | 183,837 |
Wesche Holger | Chief Scientific Officer | 10/01/2020 | 6,000 |
Wesche Holger | Chief Scientific Officer | 10/01/2020 | 162,737 |
Erbez Georgia | Chief Financial Officer | 08/19/2020 | 57,000 |
Erbez Georgia | Chief Financial Officer | 08/18/2020 | 24,337 |
Erbez Georgia | Chief Financial Officer | 07/31/2020 | 19,842 |
Wesche Holger | Chief Scientific Officer | 07/01/2020 | 6,000 |
Wesche Holger | Chief Scientific Officer | 07/01/2020 | 161,989 |
Arix Bioscience plc | 10% Owner | 05/28/2020 | 7,820,926 |
Arix Bioscience plc | 10% Owner | 05/27/2020 | 270,144 |
Sacks Natalie | Chief Medical Officer | 05/18/2020 | 3,227 |
Sacks Natalie | Chief Medical Officer | 05/18/2020 | 22,479 |
Wesche Holger | Chief Scientific Officer | 05/12/2020 | 840 |
Wesche Holger | Chief Scientific Officer | 05/12/2020 | 19,720 |
Wesche Holger | Chief Scientific Officer | 05/07/2020 | 3,210 |
Wesche Holger | Chief Scientific Officer | 05/11/2020 | 600 |
Wesche Holger | Chief Scientific Officer | 05/08/2020 | 600 |
Wesche Holger | Chief Scientific Officer | 05/07/2020 | 75,576 |
Wesche Holger | Chief Scientific Officer | 05/11/2020 | 14,065 |
Wesche Holger | Chief Scientific Officer | 05/08/2020 | 14,000 |
Sacks Natalie | Chief Medical Officer | 05/01/2020 | 12,351 |
Sacks Natalie | Chief Medical Officer | 05/01/2020 | 70,301 |
Wesche Holger | Chief Scientific Officer | 04/28/2020 | 750 |
Wesche Holger | Chief Scientific Officer | 04/28/2020 | 17,565 |
Sacks Natalie | Chief Medical Officer | 04/17/2020 | 2,165 |
Sacks Natalie | Chief Medical Officer | 04/16/2020 | 1,060 |
Sacks Natalie | Chief Medical Officer | 04/17/2020 | 12,330 |
Sacks Natalie | Chief Medical Officer | 04/16/2020 | 6,000 |
Sacks Natalie | Chief Medical Officer | 04/13/2020 | 9,659 |
Sacks Natalie | Chief Medical Officer | 04/13/2020 | 54,959 |
Sacks Natalie | Chief Medical Officer | 04/07/2020 | 1,208 |
Sacks Natalie | Chief Medical Officer | 04/06/2020 | 1,484 |
Sacks Natalie | Chief Medical Officer | 04/06/2020 | 8,401 |
Sacks Natalie | Chief Medical Officer | 04/07/2020 | 6,840 |
Sacks Natalie | Chief Medical Officer | 03/17/2020 | 3,222 |
Sacks Natalie | Chief Medical Officer | 03/16/2020 | 2 |
Sacks Natalie | Chief Medical Officer | 03/17/2020 | 18,240 |
Sacks Natalie | Chief Medical Officer | 03/16/2020 | 12 |
Sacks Natalie | Chief Medical Officer | 03/02/2020 | 12,351 |
Sacks Natalie | Chief Medical Officer | 03/02/2020 | 85,526 |
Sacks Natalie | Chief Medical Officer | 02/18/2020 | 3,225 |
Sacks Natalie | Chief Medical Officer | 02/18/2020 | 22,815 |
Sacks Natalie | Chief Medical Officer | 02/03/2020 | 12,351 |
Sacks Natalie | Chief Medical Officer | 02/03/2020 | 81,006 |
Erbez Georgia | Chief Financial Officer | 01/21/2020 | 94,418 |
Sacks Natalie | Chief Medical Officer | 01/16/2020 | 3,225 |
Sacks Natalie | Chief Medical Officer | 01/16/2020 | 22,725 |
Wesche Holger | Chief Scientific Officer | 01/02/2020 | 6,000 |
Wesche Holger | Chief Scientific Officer | 01/02/2020 | 143,987 |
Sacks Natalie | Chief Medical Officer | 01/02/2020 | 12,351 |
Sacks Natalie | Chief Medical Officer | 01/02/2020 | 82,600 |
Baeuerle Patrick | Director | 12/27/2019 | 1,396,281 |
Sacks Natalie | Chief Medical Officer | 12/16/2019 | 3,225 |
Sacks Natalie | Chief Medical Officer | 12/16/2019 | 25,888 |
Chin Mark | Director | 12/17/2019 | 209,969 |
Chin Mark | Director | 12/16/2019 | 222,680 |
Chin Mark | Director | 12/13/2019 | 189,341 |
Arix Bioscience plc | 10% Owner | 12/17/2019 | 209,969 |
Arix Bioscience plc | 10% Owner | 12/16/2019 | 222,680 |
Arix Bioscience plc | 10% Owner | 12/13/2019 | 189,341 |
Chin Mark | Director | 12/10/2019 | 2,227,019 |
Chin Mark | Director | 12/09/2019 | 1,884,445 |
Chin Mark | Director | 12/06/2019 | 914,222 |
Arix Bioscience plc | 10% Owner | 12/10/2019 | 2,227,019 |
Arix Bioscience plc | 10% Owner | 12/09/2019 | 1,884,445 |
Arix Bioscience plc | 10% Owner | 12/06/2019 | 914,222 |
Erbez Georgia | Chief Financial Officer | 12/04/2019 | 100,259 |
Sacks Natalie | Chief Medical Officer | 12/02/2019 | 12,351 |
Sacks Natalie | Chief Medical Officer | 12/02/2019 | 104,751 |
Sacks Natalie | Chief Medical Officer | 11/18/2019 | 38,694 |
Sacks Natalie | Chief Medical Officer | 11/18/2019 | 243,964 |
Sacks Natalie | Chief Medical Officer | 11/01/2019 | 12,351 |
Sacks Natalie | Chief Medical Officer | 11/01/2019 | 76,702 |
Sacks Natalie | Chief Medical Officer | 10/14/2019 | 26,398 |
Sacks Natalie | Chief Medical Officer | 10/15/2019 | 24,800 |
Sacks Natalie | Chief Medical Officer | 10/15/2019 | 154,481 |
Sacks Natalie | Chief Medical Officer | 10/14/2019 | 165,280 |
McMahon Gerald PhD | President and CEO | 06/05/2019 | 101,677 |
McMahon Gerald PhD | President and CEO | 05/14/2019 | 10,157 |
McMahon Gerald PhD | President and CEO | 05/08/2019 | 10,559 |
McMahon Gerald PhD | President and CEO | 05/03/2019 | 10,530 |
Arix Bioscience plc | 10% Owner | 02/12/2019 | 5,999,994 |
UBS Oncology Impact Fund L.P. | 10% Owner | 02/12/2019 | 3,500,000 |
UBS Oncology Impact Fund L.P. | 10% Owner | 02/12/2019 | 6,258 |
UBS Oncology Impact Fund L.P. | 10% Owner | 02/12/2019 | 6,253 |
New Leaf Ventures III, L.P. | 10% Owner | 02/12/2019 | 5,999,994 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/12/2019 | 3,500,000 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/12/2019 | 21,336 |
MPM BioVentures 2014, L.P. | 10% Owner | 02/12/2019 | 21,260 |
HUNT RONALD | Director | 02/12/2019 | 5,999,994 |
GADICKE ANSBERT | 10% Owner | 02/12/2019 | 7,000,000 |
GADICKE ANSBERT | 10% Owner | 02/12/2019 | 27,594 |
GADICKE ANSBERT | 10% Owner | 02/12/2019 | 27,513 |
Chin Mark | Director | 02/12/2019 | 5,999,994 |
EVNIN LUKE | Director | 02/12/2019 | 21,336 |
EVNIN LUKE | Director | 02/12/2019 | 3,500,000 |
EVNIN LUKE | Director | 02/12/2019 | 21,260 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. | 1,500,000 | 0.27% | New | Other |
BLACKSTONE INC. | 815,000 | 0.04% | New | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 300,000 | 0.00706% | New | Other |
BLACKROCK INC. | 249,834 | 0.00007% | 576.34% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 149,262 | 0.00018% | 499.13% | Other |
ORBIMED ADVISORS LLC | 62,121 | 0.00532% | Exited | Other |
RENAISSANCE TECHNOLOGIES LLC | 12,756 | 0.00022% | -48.68% | Other |
Period of Report: 09/30/2023
10-K/10-Q Filings: View